Payment overview · 2025
General Payments
$22,491.17
129 reported records · 24 companies
Healthcare provider profile · identity verified
Deepak Bacharanianda Muthappa, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARIS, TX · NPI 1831532241
Verified facts
What the public records show
CMS Open Payments records show Deepak Bacharanianda Muthappa, M.D. received $22,491.17 in general payments during 2025 across 129 reported records.
ABBVIE INC. accounted for 93.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy, Veozah, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Krystexxa by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21,073.79 | 93.7% | 54 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.16 | 1.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $205.12 | 0.9% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $151.02 | 0.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.53 | 0.6% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.26 | 0.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.05 | 0.4% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$70.50 | 0.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.40 | 0.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.91 | 0.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.22 | 0.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.65 | 0.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.87 | 0.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.22 | 0.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.68 | 0.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.06 | 0.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.69 | 0.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.99 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.1% | 1 | 2025 |
| scPharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.48 | 0.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.71 | 0.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.69 | 0.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.65 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,375.00 | 5 |
| Consulting Fee | $6,843.75 | 5 |
| Food and Beverage | $2,305.96 | 115 |
| Travel and Lodging | $966.46 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13,424.96 | 35 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $12,280.86 | 26 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $186.25 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $151.02 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.16 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $142.53 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $142.53 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.27 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.10 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.10 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.26 | 4 | 2025 |
Source payment records
|
|||||
| CG FUTURE Normalized: cg future |
Device | Medtronic, Inc. | $70.50 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.40 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $67.41 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.91 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.05 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.82 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.65 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.01 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.87 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.13 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | scPharmaceuticals Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 30 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 192 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 177 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 166 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 270 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 188 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
177 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
188 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
166 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
270 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1254 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1214 | 332 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1011 | 243 |
| Amlodipine Besylate | Amlodipine Besylate | 916 | 238 |
| Gabapentin | Gabapentin | 800 | 205 |
| Potassium Chloride | Potassium Chloride | 779 | 192 |
| Alprazolam | Alprazolam | 685 | 123 |
| Furosemide | Furosemide | 665 | 181 |
| Lisinopril | Lisinopril | 646 | 176 |
| Omeprazole | Omeprazole | 613 | 164 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 611 | 191 |
| Pantoprazole Sodium | Pantoprazole Sodium | 589 | 161 |
| Losartan Potassium | Losartan Potassium | 579 | 173 |
| Azithromycin | Azithromycin | 513 | 321 |
| Trazodone Hcl | Trazodone Hcl | 494 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 454 | 119 |
| Tramadol Hcl | Tramadol Hcl | 429 | 102 |
| Metformin Hcl | Metformin Hcl | 415 | 117 |
| Meloxicam | Meloxicam | 411 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 404 | 103 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 391 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 386 | 151 |
| Carvedilol | Carvedilol | 377 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 342 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 337 | 105 |
| Zolpidem Tartrate | Zolpidem Tartrate | 331 | 56 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 317 | 97 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 313 | 205 |
| Pregabalin | Pregabalin | 311 | 63 |
| Prednisone | Prednisone | 308 | 165 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 293 | 188 |
| Sertraline Hcl | Sertraline Hcl | 289 | 76 |
| Clonazepam | Clonazepam | 286 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 273 | 54 |
| Ozempic | Semaglutide | 270 | 62 |
| Montelukast Sodium | Montelukast Sodium | 259 | 70 |
| Lorazepam | Lorazepam | 251 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 227 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 222 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 213 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 52 |
| Celecoxib | Celecoxib | 201 | 49 |
| Allopurinol | Allopurinol | 199 | 52 |
| Buspirone Hcl | Buspirone Hcl | 199 | 43 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 195 | 119 |
| Eliquis | Apixaban | 192 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 188 | 55 |
| Simvastatin | Simvastatin | 186 | 50 |
| Farxiga | Dapagliflozin Propanediol | 177 | 48 |
| Ezetimibe | Ezetimibe | 171 | 44 |
| Famotidine | Famotidine | 171 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 171 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 44 |
| Methocarbamol | Methocarbamol | 167 | 42 |
| Mounjaro | Tirzepatide | 166 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 158 | 74 |
| Spironolactone | Spironolactone | 154 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 152 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 149 | 92 |
| Ondansetron Odt | Ondansetron | 146 | 68 |
| Alendronate Sodium | Alendronate Sodium | 141 | 38 |
| Glipizide | Glipizide | 140 | 34 |
| Levetiracetam | Levetiracetam | 134 | 24 |
| Ibuprofen | Ibuprofen | 131 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 126 | 38 |
| Glimepiride | Glimepiride | 124 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 55 |
| Fluconazole | Fluconazole | 121 | 74 |
| Cephalexin | Cephalexin | 120 | 72 |
| Finasteride | Finasteride | 117 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 32 |
| Diazepam | Diazepam | 111 | 29 |
| Temazepam | Temazepam | 110 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 109 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 31 |
| Promethazine Hcl | Promethazine Hcl | 109 | 27 |
| Xarelto | Rivaroxaban | 108 | 24 |
| Donepezil Hcl | Donepezil Hcl | 107 | 21 |
| Memantine Hcl | Memantine Hcl | 107 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 23 |
| Torsemide | Torsemide | 96 | 24 |
| Atenolol | Atenolol | 94 | 22 |
| Warfarin Sodium | Warfarin Sodium | 92 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 17 |
| Jardiance | Empagliflozin | 86 | 28 |
| Levofloxacin | Levofloxacin | 84 | 61 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 82 | 24 |
| Januvia | Sitagliptin Phosphate | 82 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 28 |
| Estradiol | Estradiol | 80 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 20 |
| Mirtazapine | Mirtazapine | 79 | 15 |
| Sucralfate | Sucralfate | 79 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 76 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 74 | 45 |
| Nystatin | Nystatin | 74 | 50 |
| Mupirocin | Mupirocin | 71 | 52 |
| Latanoprost | Latanoprost | 70 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 70 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 47 |
| Linzess | Linaclotide | 67 | 23 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 65 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 64 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 62 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 43 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 17 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Fentanyl | Fentanyl | 56 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 18 |
| Metformin Hcl Er | Metformin Hcl | 55 | 17 |
| Aripiprazole | Aripiprazole | 54 | 15 |
| Meclizine Hcl | Meclizine Hcl | 54 | 22 |
| Propranolol Hcl | Propranolol Hcl | 54 | 13 |
| Clonidine | Clonidine | 53 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 11 |
| Topiramate | Topiramate | 53 | 16 |
| Bumetanide | Bumetanide | 52 | 17 |
| Enalapril Maleate | Enalapril Maleate | 51 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 23 |
| Lovastatin | Lovastatin | 48 | 11 |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Olanzapine | Olanzapine | 47 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Enulose | Lactulose | 45 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Rybelsus | Semaglutide | 42 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 42 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 41 | 18 |
| Folic Acid | Folic Acid | 39 | 12 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 27 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 21 |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | 13 |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 20 |
| Colchicine | Colchicine | 34 | 14 |
| Valsartan | Valsartan | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | 11 |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Calcitriol | Calcitriol | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | 11 |
| Metronidazole | Metronidazole | 29 | 23 |
| Nitroglycerin | Nitroglycerin | 29 | 22 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 19 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 26 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Veozah | Fezolinetant | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 18 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Humira(Cf) | Adalimumab | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Erythromycin | Erythromycin Base | 21 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Celebrex | Celecoxib | 20 | suppressed |
| Lactulose | Lactulose | 20 | 15 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 20 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Krystexxa | Pegloticase | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,491.17 · 129 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CG FUTURE, CREON, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, FUROSCIX, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error